Page 2 of 5

Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial

New article on the treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial from the Lancet Infectious Diseases

Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial

The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial

New publication on The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial from the American Heart Journal

The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial

#vascularaccess #FOAMva #FOAMed #FOAMcc #FOAMus #FOAMrad #FOAMped #FOAMem

Poor adherence to guidelines for preventing central line-associated bloodstream infections (CLABSI): results of a worldwide survey

New article on review of worldwide CLABSI due to poor guideline adherence from the journal Antimicrobial Resistance & Infection Control

Poor adherence to guidelines for preventing central line-associated bloodstream infections (CLABSI): results of a worldwide survey

#vascularaccess #FOAMva #FOAMed #FOAMcc #FOAMems #FOAMrad #infectionprevention #CLABSI